Roberto Iacone, Alentis Therapeutics CEO
November 12, 2024 07:00 AM EST
Financing
Startups

Alen­tis nabs $181M to broad­en Claud­in's scope in AD­Cs

Kyle LaHucik

Senior Reporter

Swiss biotech Alen­tis Ther­a­peu­tics thinks it can ex­pand the reach of the Claudin fam­i­ly in on­col­o­gy, and half a dozen new in­vestors are help­ing back …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

No­vo Nordisk’s once-dai­ly he­mo­phil­ia drug Al­he­mo ap­proved in US

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

GSK's Ze­ju­la-Jem­per­li com­bo in ovar­i­an can­cer hits pri­ma­ry end­point, miss­es on over­all sur­vival

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

A service from the Financial Times